Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 9, 2010 - Issue 2
Submit an article Journal homepage
575
Views
42
CrossRef citations to date
0
Altmetric
Reviews

Toxicity of sorafenib: clinical and molecular aspects

Benoit Blanchet Laboratoire de Pharmacologie-Toxicologie, Service de Pharmacie, GH Cochin-Saint Vincent-de-Paul, 75014 Paris, France + 33 1 58 41 23 13; + 33 1 58 41 23 15;[email protected]; Centre d’Evaluation et de Recours sur les Inhibiteurs de l’Angiogénèse (CERIA), GH Cochin-Saint Vincent-de-Paul, APHP, Paris, France
, PharmD PhD,
Bertrand Billemont Unité d’Oncologie, GH Cochin-Saint Vincent-de-Paul, Paris, France; Centre d’Evaluation et de Recours sur les Inhibiteurs de l’Angiogénèse (CERIA), GH Cochin-Saint Vincent-de-Paul, APHP, Paris, France
,
Stéphane Barete Centre d’Evaluation et de Recours sur les Inhibiteurs de l’Angiogénèse (CERIA), GH Cochin-Saint Vincent-de-Paul, APHP, Paris, France; Département de Dermatologie, Hôpital Tenon, APHP, Paris, France
,
Hélène Garrigue Unité de Radiopharmacie, Service de Pharmacie, GH Cochin-Saint Vincent-de-Paul, Paris, France; Centre d’Evaluation et de Recours sur les Inhibiteurs de l’Angiogénèse (CERIA), GH Cochin-Saint Vincent-de-Paul, APHP, Paris, France
,
Laure Cabanes Service de Cardiologie, GH Cochin-Saint Vincent-de-Paul, Paris, France; Centre d’Evaluation et de Recours sur les Inhibiteurs de l’Angiogénèse (CERIA), GH Cochin-Saint Vincent-de-Paul, APHP, Paris, France
,
Romain Coriat Service de Gastro-entérologie, GH Cochin-Saint Vincent-de-Paul, Paris, France; Centre d’Evaluation et de Recours sur les Inhibiteurs de l’Angiogénèse (CERIA), GH Cochin-Saint Vincent-de-Paul, APHP, Paris, France
,
Camille Francès Centre d’Evaluation et de Recours sur les Inhibiteurs de l’Angiogénèse (CERIA), GH Cochin-Saint Vincent-de-Paul, APHP, Paris, France; Département de Dermatologie, Hôpital Tenon, APHP, Paris, France
,
Bertrand Knebelmann Service de Néphrologie, Hôpital Necker, APHP, Paris, France
&
François Goldwasser Unité d’Oncologie, GH Cochin-Saint Vincent-de-Paul, Paris, France; Centre d’Evaluation et de Recours sur les Inhibiteurs de l’Angiogénèse (CERIA), GH Cochin-Saint Vincent-de-Paul, APHP, Paris, France; EA 1833 Faculté de Médecine Paris Descartes, Paris, France
 show all
Pages 275-287 | Published online: 17 Jan 2010

Citations (42)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Claudio Cerchione, Andrés Peleteiro Raíndo, Adrián Mosquera Orgueira, Alicia Mosquera Torre, Laura Bao Pérez, Giovanni Marconi, Alessandro Isidori, Manuel Mateo Pérez Encinas & Giovanni Martinelli. (2021) Safety of FLT3 inhibitors in patients with acute myeloid leukemia. Expert Review of Hematology 14:9, pages 851-865.
Read now
William H. Smith, Amy S. Law, Miriam Hulkower, Heather M. McGee, Eric J. Lehrer, Myron Schwartz, Bachir Taouli, Max Sung & Michael Buckstein. (2020) The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. Acta Oncologica 59:8, pages 940-943.
Read now
Zeran Yang, Guang Chen, Ye Cui, Guowen Xiao, Tianhao Su, Jianan Yu, Zhiyuan Zhang, Yanjing Han, Kailan Yang & Long Jin. (2019) The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biology & Therapy 20:3, pages 321-327.
Read now
Chun-Bing Chen, Ming-Ying Wu, Chau Yee Ng, Chun-Wei Lu, Jennifer Wu, Pei-Han Kao, Chan-Keng Yang, Meng-Ting Peng, Chen-Yang Huang, Wen-Cheng Chang, Rosaline Chung-Yee Hui, Chih-Hsun Yang, Shun-Fa Yang, Wen-Hung Chung & Shih-Chi Su. (2018) Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Management and Research 10, pages 1259-1273.
Read now
Olivier Huillard, Emilie Boissier, Benoit Blanchet, Audrey Thomas-Schoemann, Anatole Cessot, Pascaline Boudou-Rouquette, Jean-Philippe Durand, Romain Coriat, Julie Giroux, Jerome Alexandre, Michel Vidal & Francois Goldwasser. (2014) Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Expert Opinion on Drug Safety 13:5, pages 663-673.
Read now
Joanna Mangana, Mitchell P Levesque, Maria B Karpova & Reinhard Dummer. (2012) Sorafenib in melanoma. Expert Opinion on Investigational Drugs 21:4, pages 557-568.
Read now
Renuka Iyer, Gerald Fetterly, Amit Lugade & Yasmin Thanavala. (2010) Sorafenib: a clinical and pharmacologic review. Expert Opinion on Pharmacotherapy 11:11, pages 1943-1955.
Read now

Articles from other publishers (35)

Youhao Chen, Yaobin Lin, Shaoxing Guan, Zerui Zhao, Daren Lin, Jin Guan, Chengzhi Zhou, Junling Liu, Xiaolong Cao, Zhichao Lin, Diyao Chen, Jianbiao Shang, Weijian Zhang, Huohui Chen, Likun Chen, Shudong Ma, Lijia Gu, Jian Zhao, Min Huang, Xueding Wang & Hao Long. (2023) The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors. Drug Metabolism and Disposition 51:12, pages 1583-1590.
Crossref
Parul D. Agarwal, Michael R. Lucey, Adnan Said & Jeremy Kratz. (2023) Immunotherapy for HCC: limitations in patients with NASH. Annals of Hepatology 28:2, pages 100886.
Crossref
Xinhong Fei, Shuqin Zhang, Jiangying Gu & Jingbo Wang. (2022) FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta‐analysis . Cancer Medicine 12:6, pages 6877-6888.
Crossref
Inés Roger, Paula Montero, Martín Pérez-Leal, Javier Milara & Julio Cortijo. (2023) Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview. Cancers 15:4, pages 1208.
Crossref
Catherine Wegner Wippel, Hari Deshpande, Huned Patwa & Aldo J Peixoto. (2022) Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Reports 15:12, pages e247140.
Crossref
Nasrin Nassiri Koopaei, Mehrasa Shademani, Nasrin Shirzad Yazdi, Raheleh Tahmasvand, Mina Dehbid, Mansur Nassiri Koopaei, Homa Azizian, Zahra Mousavi, Ali Almasirad & Mona Salimi. (2022) Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity. BMC Chemistry 16:1.
Crossref
Yuwei LiuDongyang Wang & Xingshun Qi. (2022) Skin Rash After Camrelizumab and Sorafenib in a Patient With Advanced Hepatocellular Carcinoma. The International Journal of Gastroenterology and Hepatology Diseases 1:2.
Crossref
In Young Jo, Hee Chul Park, Eun Seog Kim, Seung-Gu Yeo, Myungsoo Kim, Jinsil Seong, Jun Won Kim, Tae Hyun Kim, Won Sup Yoon, Bae Kwon Jeong, Sung Hwan Kim & Jong Hoon Lee. (2022) Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08). Japanese Journal of Clinical Oncology 52:6, pages 616-622.
Crossref
Chia-Yu Chu. 2022. Drug Eruptions. Drug Eruptions 303 316 .
M. Nazim Abbas, Wei Son Tan & Ganessan Kichenadasse. (2021) Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. Journal of Medical Case Reports 15:1.
Crossref
Graziele Baldan Ferrari, Júlia Coelho França Quintanilha, Marília Berlofa Visacri, Camila Oliveira Vaz, Maria Aparecida Cursino, Laís Sampaio Amaral, Brito Bastos, Taynna Tatiane Pereira, João Paulo de Oliveira Guarnieri, Nadine de Godoy Torso, Carmen Silvia Passos Lima & Patricia Moriel. (2020) Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life. Anti-Cancer Drugs 31:5, pages 523-527.
Crossref
Jianping Wu, Yao Huang, Qian Xie, Junfeng Zhang & Zhen Zhan. (2020) A novel bis-aryl urea compound inhibits tumor proliferation via cathepsin D-associated apoptosis. Anti-Cancer Drugs 31:5, pages 500-506.
Crossref
William H. Smith, Meng Ru, Heather M. McGee, Max Sung, Kenneth E. Rosenzweig & Michael Buckstein. (2020) Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma. Journal of Radiation Oncology 9:1-2, pages 45-52.
Crossref
Hai le Ba, Litaty Mbatchi, Florence Gattacceca, Alexandre Evrard, Bruno Lacarelle, Benoit Blanchet, Joseph Ciccolini & Sébastien Salas. (2020) Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake. Pharmacogenomics 21:3, pages 173-179.
Crossref
Elisa Callegari, Lucilla D’Abundo, Paola Guerriero, Carolina Simioni, Bahaeldin K. Elamin, Marta Russo, Alice Cani, Cristian Bassi, Barbara Zagatti, Luciano Giacomelli, Stella Blandamura, Farzaneh Moshiri, Simona Ultimo, Antonio Frassoldati, Giuseppe Altavilla, Laura Gramantieri, Luca Maria Neri, Silvia Sabbioni & Massimo Negrini. (2018) miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Molecular Therapy - Nucleic Acids 11, pages 485-493.
Crossref
Valentina Giglio, Maurizio Viale, Vittorio Bertone, Irena Maric, Rita Vaccarone & Graziella Vecchio. (2017) Cyclodextrin polymers as nanocarriers for sorafenib. Investigational New Drugs 36:3, pages 370-379.
Crossref
Chau Yee Ng, Chun-Bing Chen, Ming-Ying Wu, Jennifer Wu, Chih-Hsun Yang, Rosaline Chung-Yee Hui, Ya-Ching Chang & Chun-Wei Lu. (2018) Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies. Journal of Immunology Research 2018, pages 1-9.
Crossref
Alicja Puszkiel, Gaëlle Noé, Audrey Thomas-Schoemann, Audrey Bellesoeur, Pascaline Boudou-Rouquette, Michel Vidal, François Goldwasser & Benoit Blanchet. (2017) Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma. International Journal of Pharmacokinetics 2:4, pages 257-283.
Crossref
Francesca Garuti, Vittoria Camelli, Luca Spinardi, Laura Bucci & Franco Trevisani. (2016) Osteonecrosis of the Jaw during Sorafenib Therapy for Hepatocellular Carcinoma. Tumori Journal 102:2_suppl, pages S69-S70.
Crossref
Xiaoxiao Sun, Qiaoling Song, Li He, Lei Yan, Jingli Liu, Qing Zhang & Qiang Yu. (2016) Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment. Molecular Cancer Therapeutics 15:10, pages 2508-2520.
Crossref
Guo-Rui Gao, Meng-Yuan Li, Yong-Cong Lv, Su-Fen Cao, Lin-Jiang Tong, Li-Xin Wei, Jian Ding, Hua Xie & Wen-Hu Duan. (2016) Design, synthesis and biological evaluation of biphenylurea derivatives as VEGFR-2 kinase inhibitors (II). Chinese Chemical Letters 27:2, pages 200-204.
Crossref
Nikki Tang & Desiree Ratner. (2016) Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer. Dermatologic Surgery 42:Supplement 1, pages S40-S48.
Crossref
James B. Macdonald, Brooke Macdonald, Loren E. Golitz, Patricia LoRusso & Aleksandar Sekulic. (2015) Cutaneous adverse effects of targeted therapies. Journal of the American Academy of Dermatology 72:2, pages 203-218.
Crossref
Emilie Hénin, Benoit Blanchet, Pascaline Boudou-Rouquette, Audrey Thomas-Schoemann, Gilles Freyer, Michel Vidal, François Goldwasser & Michel Tod. (2013) Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS). Cancer Chemotherapy and Pharmacology 73:2, pages 287-297.
Crossref
Snezana Djordjevic & Paul C. Driscoll. (2013) Targeting VEGF signalling via the neuropilin co-receptor. Drug Discovery Today 18:9-10, pages 447-455.
Crossref
Olivier Bouché & Pierre Laurent-PuigR. Coriat, P. Boudou-Rouquette & F. Goldwasser. 2013. Médecine personnalisée en cancérologie digestive. Médecine personnalisée en cancérologie digestive 305 313 .
Marilyne Hornecker, Benoit Blanchet, Bertrand Billemont, Hind Sassi, Stanislas Ropert, Fabrice Taieb, Olivier Mir, Halim Abbas, Laura Harcouet, Romain Coriat, Alain Dauphin, François Goldwasser & Michel Tod. (2011) Saturable absorption of sorafenib in patients with solid tumors: a population model. Investigational New Drugs 30:5, pages 1991-2000.
Crossref
Syu-Ichi Kanno. (2012) Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines. Molecular and Clinical Oncology.
Crossref
Gagan Deep, Subhash Chander Gangar, Subapriya Rajamanickam, Komal Raina, Mallikarjuna Gu, Chapla Agarwal, Nicholas H. Oberlies & Rajesh Agarwal. (2012) Angiopreventive Efficacy of Pure Flavonolignans from Milk Thistle Extract against Prostate Cancer: Targeting VEGF-VEGFR Signaling. PLoS ONE 7:4, pages e34630.
Crossref
Philip J. Johnson. 2011. Clinical Dilemmas in Primary Liver Cancer. Clinical Dilemmas in Primary Liver Cancer 154 159 .
Andrew S. Epstein, Eileen M. O’Reilly, Maeve Lowery, Ali Shamseddine, Jinru Shia, Sally Temraz, Ashwaq Al-Olayan, Mohamed Naghy, David Kelsen, Manish A. Shah & Ghassan K. Abou-Alfa. (2010) A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management. Journal of Gastrointestinal Cancer 42:4, pages 236-240.
Crossref
Michel Tod, Olivier Mir, Natacha Bancelin, Romain Coriat, Audrey Thomas-Schoemann, Fabrice Taieb, Pascaline Boudou-Rouquette, Stanislas Ropert, Judith Michels, Halim Abbas, Jean Philippe Durand, Alain Dauphin, Michel Vidal, Francois Goldwasser & Benoit Blanchet. (2011) Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients. Pharmaceutical Research 28:12, pages 3199-3207.
Crossref
Charline Gomo, Romain Coriat, Lionel Faivre, Olivier Mir, Stanislas Ropert, Bertrand Billemont, Alain Dauphin, Michel Tod, Francois Goldwasser & Benoit Blanchet. (2010) Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Investigational New Drugs 29:6, pages 1511-1514.
Crossref
David S. HongMaria E. CabanillasJennifer Wheler, Aung NaingApostolia M. TsimberidouLei YeSteven G. WaguespackMike HernandezAlder K. El NaggarSavita BidyasarJohn Wright, Steven I. ShermanRazelle Kurzrock. (2011) Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies. The Journal of Clinical Endocrinology & Metabolism 96:4, pages 997-1005.
Crossref
Oliver Waidmann, Wolf-Peter Hofmann, Stefan Zeuzem & Joerg Trojan. (2011) mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. Journal of Hepatology 54:2, pages 396-398.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.